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Purpose: The aim of this study was to evaluate health-related quality of life (HRQOL) in patients with different 
body mass index (BMI, <25 vs ≥ 25) undergoing radiation treatment for head and neck cancer.  
Methods: HRQOL was examined by the European Organization for Research and Treatment of Cancer 
(EORTC) QLQ-C30 and the EORTC QLQ-H&N35, in the beginning and in the end of radiation treatment in 60 
patients treated at University Hospital in Northern Norway. Information about nutritional status with weight loss, 
hemoglobin level (Hb), serum albumin and a study- specific questionnaire also was filled out in the beginning 
and in the end of treatment. The patients` general condition, skin and mucous membranes (CTCAE v.3.0) 
(grades 1 to 5 with unique clinical descriptions) were documented four times during radiation treatment. 
Changes in HRQOL were calculated and compared by paired sample T-test. Multiple regression analyses were 
used to examine correlations between baseline BMI and changes in HRQOL, CTCAE v.3.0 toxicity, nutritional 
status and information that radiotherapists provided to patients. 
Results: Patients with BMI ≥ 25 had less mucosal changes after two weeks of radiation treatment than patients 
with BMI < 25 (p= 0.010). Differences regarding feeding tube use (p= 0.037) and intake of nutritional 
supplements before radiation treatment (p= 0.001) were also seen. Patients with overweight had more dyspnea 
(p= 0.033) before treatment and more problems with dry mouth (p= 0.042) after treatment. During treatment 
patients with BMI ≥25 had more problems with opening mouth (p= 0.034) than patients with BMI <25 and more 
changes in sexuality (p= 0.019). Patients with BMI ≥ 25 received less information about food and drink 
(p=0.011) in the radiation treatment period than normal weight patients.   
Conclusions: BMI influences HRQOL and toxicity. Additional longitudinal studies should examine whether or 
not overweight patients persistently experience more problems with dry mouth and opening their mouth. 
Regardless of BMI, all patients should be informed about nutritional recommendations during treatment. 
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Introduction                                                                                                                                                   
Patients with head and neck cancer are at high risk for malnutrition due to dysphagia from the tumor itself and 
treatment toxicity. It is estimated that 25-57% of cancer patients with tumors in the oral cavity or pharynx 
already have an impaired nutrition status at the time of diagnosis and before beginning treatment [1,2] . 
Radiotherapy (RT) often results in mucositis, xerostomia, dysphagia, hoarseness, nausea and vomiting [3]. 
Approximately 30% of patients experience weight loss and associated morbidity during treatment [4].  
It is a reliable indicator of malnutrition if patients lose more than 5% of their usual body weight (BW) in 1 
month, or 2% in 1 week [4].  Poor nutrition diminishes the ability of the immune system to function effectively 
[5] and increases the risk of infections, hospitalization, and treatment interruption, potentially resulting in poor 
treatment outcomes [6]. Studies found that maintaining adequate nutrition before and during treatment can 
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decrease weight loss, help to avoid dehydration, and lead to better tolerance without treatment interruptions 
[4,7].  
Previous studies have shown that quality of life in head and neck cancer patients is lower at diagnosis compared 
with the general population, and becomes worse during and immediately after treatment [8,9]. Women score 
lower than men at diagnosis and immediately after treatment [10,11] and patients > 65 years of age score lower 
in quality of life studies than those under 65 [11]. In addition, tumor size, smoking, alcohol abuse, depression, 
social network, personality and marital status can affect the quality of life of head and neck cancer patients [12-
17].  
However, few studies have focused on the effect of body mass index (BMI) on treatment outcomes [18]. The 
World Health Organization (WHO) defines overweight as body mass index (BMI) 25-29.9 kg/m2 and obesity as 
BMI ≥30. Obesity is characterized by a number of side effects; among others obesity reduces quality of life and 
physical activity [19].   
There are several reasons why quality of life studies in head and neck cancer patients are important. Better 
understanding of therapeutic healing aspects will help staff to be able to inform patients and thus prepare them 
for any function changes and symptoms during RT. Better understanding of different health aspects is also 
essential for preventing and mitigating functional impairment and symptoms. Although much research has been 
done regarding quality of life, function and symptoms, there are still areas that are less well explored. It is for 
example unclear how overweight and obesity can affect the quality of life of patients undergoing RT. Therefore, 
we conducted a secondary analysis of a prospective study to evaluate whether BMI was associated with quality 
of life during RT in head and neck cancer patients. The prospective single-arm study was designed to follow 
head and neck cancer patients during their radiation treatment period with the purpose to document how the 
patients experienced the radiotherapy period in terms of information needs, side effects and quality of life. There 
are four earlier publications regarding primary aspects of this study [20-23].             
 
Methods                                                                                                                                                                  
Study design and patient sample                                                                                                                            
The study was conducted at the University Hospital in Northern Norway, in the time period from May 2009 to 
November 2012. All ambulatory adult patients (18 years or older) with an untreated primary head and neck 
cancer, referred to the oncology center for radiotherapy, were potentially eligible to participate in the study. 
Exclusion criteria were patients who were unable to answer the health-related quality of life (HRQOL) 
questionnaires as a result of mental disturbance, or unable to fill in the questionnaire for other reasons, e.g., poor 
general condition, or if they were unable to speak and understand Norwegian. Totally 87 potentially eligible 
patients were originally identified. Eligible patients received a letter explaining the purpose and the methods of 
the study and the level of commitment required to participate. A research assistant met the patients during 
treatment planning or initiation to seek consent and administer the questionnaire. Eighty-two patients met the 
criteria and were invited to attend the study. Three patients refused participation and one relative of a patient 
declined. Eleven patients did not return the written consent. Sixty-seven were included, providing an attendance 
rate of 82.7%. Sixty patients had available BMI data. The study was approved by the Regional Committee for 
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Medical Research Ethics (P REK NORD 200900504-3KST017/400), and the Norwegian Social Science Data 
Services (21831).                                                                                                                                 
Data collection                                                                                                                                                      
Socio demographic and tumor-related patient characteristics were recorded at inclusion, i.e. sex, age, tumor 
location according to ICD-10, TNM stage (T=tumor size, N=node, M= metastasis) and planned treatment. In 
addition, a study-specific questionnaire about which information the health care workers had given the patients 
was filled out twice by the research radiation therapist, before the patients started treatment and after they 
completed treatment. The patients responded to what information they had received about nutrition and which 
food and drinks they should avoid during the radiation treatment period. Information regarding dietary 
counselling was not structured before or under radiation treatment; the doctors, nurses and radiation therapists 
gave individual dietary advice. The patients were provided with verbal nutrition information from the radiation 
therapists during the treatment. They were not encouraged to use media or websites to gain further information. 
The nutrition information questionnaire consisted of open questions where the patients should answer the 
radiation therapist. Patients were also asked about current use of nutritional supplements such as powders or 
liquids providing extra calories, and if they wanted to talk to a nutritionist. In addition, nutritional status with 
weight loss, hemoglobin level (Hb) and serum albumin was filled out in the beginning (0Gy), after 2 weeks 
(20Gy), after 4 weeks (40Gy) and after 6 weeks (60Gy) by the research radiation therapist. The patients` general 
condition, skin and mucous membranes (CTCAE v.3.0) (mucositis clinical, grades 1 to 5 with unique clinical 
descriptions) were documented by the research radiation therapist four times during radiation treatment, in the 
beginning (0Gy), after 2 weeks (20Gy), after 4 weeks (40Gy) and after 6 weeks (60Gy).                                                                                                                                                         
HRQOL questionnaires                                                                                                                                         
Data were collected at two time points: at baseline which was the first radiation treatment week (T1), and during 
the last week after 60 Gy (T4). At T1 and T4, the patients filled in the European Organization for Research and 
Treatment of Cancer (EORTC) QLQ-C30 [24] and EORTC QLQ-H&N35 [25]. The EORTC QLQ-C30 
questionnaire is a generic questionnaire to all cancers. The questionnaire is a patient-based measurement 
designed for self-administration which assesses multiple dimensions of HRQOL and responses of this 30-item 
questionnaire are categorized into five functional domains (physical, role, emotional, cognitive, and social) 
scored on a four-point scale, one global HRQOL domain (scored on a seven-point scale), three symptom 
domains (fatigue, nausea/vomiting, pain) and six single items (scored on a four-point scale). Each score is 
transformed into 0-100 point scale. Both EORTC instruments were scored according to recommendations in the 
EORTC QLQ-C30 scoring manual [8]. In the five functional scales and the global HRQOL scale, a high score 
represents a high level of functioning or global HRQOL. In the symptom scales and single items, a higher score 
implies a high level of symptoms or problems. EORTC QLQ-H&N35 is a questionnaire specifically developed 
for head and neck cancer patients consisting of 35 items on health-related HRQOL. It includes seven scales 
(pain, swallowing, senses, speech, social eating, social contact and sexuality) and 11 single items (problems with 
teeth, problems opening the mouth, dry mouth, sticky salvia, cough, feeling ill, pain killers, nutritional 
supplements, feeding tube, weight loss and weight gain). Items 1-30 are scored on a four-point scale (1; not at 
all, 2; a little, 3; quite a bit, 4; very much). Items 31-35 have a yes (2) or no (1) response format. Given that all 
the scales assess symptoms, higher scores correspond to lower quality of life.  
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Clinical treatment                                                                                                                                                                  
Radiotherapy was administered to the primary tumor and the regional neck lymphatics (dependent on N stage) 
by conventional fractionation, i.e. dose of 2 Gy, 1 fraction per day, 5 days per week. The total radiation doses 
were 60-70 Gy. RT was delivered using megavoltage equipment (6MV linear accelerator) over a period of six to 
seven weeks. In all patients, thermoplastic mask immobilization and planning computed tomography scans were 
used, and all patients were treated with three-dimensional conformal (n=48) or intensity-modulated radiotherapy 
(n=12). None of the patients had distant metastases. The patients received standardized oral care kits before 
radiotherapy, which contained soft toothbrush, flourished toothpaste without soap, artificial salvia spray and 
lozenges, fluoride mouthwash, saltwater and dexpanthenol lotion. Further counseling was individualized. 
Statistical analysis                                                                                                                                                         
In the present study, the primary outcome of interest was to examine correlations between obesity and quality of 
life during RT. Secondary outcomes were differences in information that obese patients received compared to 
normal weight patients regarding nutrition. Sixty patients with available BMI data were included. Changes in 
HRQOL were calculated and compared by paired sample T-test. Multiple regression analyses were used to 
examine correlations between baseline BMI and changes in HRQOL, CTCAE v.3.0 toxicity, nutritional status 
and information that radiotherapists provided to patients. To obtain the latter parameter, patients’ answers were 
converted to a three-tiered score, which was compared between groups by Pearson Chi-Square test. Baseline 
frequency data were compared by Fisher exact probability test. The significance level was set at p= 0.05 using 
the statistical software SPSS 19.0 for Windows.  
 
Results                                                                                                                                                                
Mean age of all 60 patients was 60 years. Seventy-seven percent were males (Table 1). Twenty-five percent were 
never smokers. Mean BMI was 25.7 (<25 in 26 patients, 43%). There were 9 obese (BMI > 30) patients, and 1 
underweight (BMI < 18.5) patient. The differences in baseline parameters included in Table 1 (for example 
chemotherapy utilization, baseline weight loss or gender) between overweight and normal weight patients were 
not statistically significant. There was no statistically significant difference in baseline Hb and serum albumin 
between overweight and normal weight patients either (Table 2). As also shown in Table 2, BMI decreased 
slightly during radiotherapy, both in overweight and normal weight patients. Numerical decreases in Hb and 
albumin were also found. The magnitude of these changes was similar in both groups.         
Table 3 shows that quality of life (EORTC QLQ-C30) was largely comparable at baseline, except for dyspnea 
which was significantly worse in overweight patients. Differences between baseline and end of treatment were 
similar in both groups. Table 4 shows the results of the QLQ-H&N35 questionnaire. At baseline, overweight 
patients had lower rates of feeding tube use (p= 0.037) and intake of nutritional supplements (p= 0.001). At end 
of treatment, overweight patients had significantly more problems with dry mouth (p= 0.042). During treatment 
patients with BMI ≥ 25 had more problems with opening mouth (p= 0.034) than patients with BMI < 25 and 
more changes in sexuality (p= 0.019). The persistent differences in feeding tube use lie below the border of 
statistical significance.  
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Table 5 shows that patients with BMI  ≥ 25 had less mucosal changes after two weeks of radiation treatment than 
patients with BMI < 25 (p= 0.010), and comparable trends were seen at later time points. However, this 
difference was not statistically significant at later time points when the higher cumulative radiation doses 
generally caused more severe side effects. Course of skin changes and performance status was not clearly related 
to BMI. Patients with BMI ≥ 25 received less information about food and drinks that they should avoid in the 
radiation treatment period than normal weight patients (p= 0.011), although general nutrition information was 
comparable between the groups (Table 6).   
 
Table 1 Pretreatment body mass index and other baseline parameters 
Patient characteristics                                                   All n(%)  
60(100)  
BMI <25 n(%) 
26(43.3) 





Mean (min, max) 
 






















Oral cavity n(%)  
Pharynx n(%) 
Larynx n(%) 
Salivary glands n(%)  
Others/unknown n(%) 




























































































































Present smoker n(%) 
Former smoker n(%) 

















Baseline weight loss* n(%) 12(20) 7(26.9) 5(14.7)  0.187 
 
*Patients who reported weight loss on EORTC QLQ-H&N 35 form, no quantification required 
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Table 2 Patients’ BMI, hemoglobin and albumin before and during treatment                                                         
                                                 
All  
 
BMI <25 (n=26) 
  
BMI ≥25 (n=34) 
 
             P-value 
BMI 
0 Gy  mean, range  
20 Gy mean, range  
40Gy  mean, range  






















0Gy [g/dl];  mean, range 
20Gy [g/dl];  mean, range 
40Gy [g/dl];  mean, range 
60Gy [g/dl];  mean, range 
 
13.7, 7.5 
 13.8, 6.3 
 13.2, 6.4 




 13.0, 5.0 
 12.7, 4-9 
 
 14.1, 6.5         
 14.0, 6.3 
 13.4, 6.4 







0 Gy [g/l]; mean, range 
20 Gy [g/l];  mean, range 
40 Gy [g/l];  mean, range 
60 Gy [g/l];  mean, range 
 
42.2, 15.3 
 41.2, 24.4 
40.0, 22.3 
 38.9, 19.8 
 
42.3, 15.3 
 40.5, 23.5 
 40.5, 17.4 
 39.1, 17.2 
 
42.1, 11.1 
 41.4, 12.9 




























































76.4, 25.5 44.8, 31.2, 
0.213 







87.2, 20.3    75.0, 24.5, 
0.733 







86.1, 17.5 78.3, 25.2, 
0.187 







73.6, 26.0 60.1, 30.9, 
0.843 







65.6, 24.6 48.3, 25.7, 
0.527 
47.8, 25.5 21.9, 19.4, 
0.820 
21.6, 26.7 
Symptom scale       
Fatigue 32.3, 25.6, 
0.816 
31.9, 21.8 53.7, 30.5, 
0.236 







17.4, 26.2    33.3, 30.0, 
0.471 
25.4, 28.8 -19.2, 29.3, 
0.670 
-9.8, 32,4 
Pain 15.2, 18.5, 
0.919 
18.1, 20.8 44.4, 30.7, 
0.078 






      
Dyspnea 22.5, 21.3, 
0.033 
16.7, 26.0 22.2, 22.0, 
0.401 
30.4, 31.6 -1.1, 20.5, 
0.349 
-15.2, 22.4 
Insomnia 26.5, 29.3, 
0.395 
33.3, 34.0 25.6, 27.2, 
0.343 
34.8, 34.0 1.1, 27.0, 
0.135 
-3.0, 34.0 
Loss of appetite 17.6, 29.9, 
0.732 
22.2, 35.0 57.8, 37.1, 
0.826 





Constipation 17.2, 23.7, 
0.607 
20.8, 27.5 46.7, 38.8, 
0.922 
47.8, 38.7 -31.0, 46.2, 
0.961 
-34.8, 39.1 
Diarrhea 14.1, 23.6, 
0.773 
13.9, 21.8 17.8, 31.2, 
0.253 







18.1, 31.1 15.6, 24.3, 
0.263 



















































Swallowing 6.9, 12.0, 
0.081 
11.6, 16.1 45.7, 31.6, 
0.281 
45.3, 28.1 -38.2, 35.0, 
0.651 
-35.6, 26.8 
Senses problems 14.2, 24.7, 
0.352 
26.7, 28.9    50.6, 31.7, 
0.217 
55.8, 30.0 -35.6, 35.8, 
0.405 
-31.2, 25.3 
Speech problems 13.1, 14.6, 
0.268 
23.1, 25.8 39.8, 27.3, 
0.137 







18.8, 23.0 48.3, 26.7, 
0.652 







6.1, 11.0 23.0, 24.8, 
0.288 
28.9, 29.9 -18.4, 22.1, 
0.479 
-22.6, 30.4 
Less sexuality 30.1, 29.5, 
0.345 
34.8, 37.1  53.2, 32.3, 
0.450 
41.6, 33.8 -28.3, 33.1, 
0.019 
-8.8, 44.5 
Teeth 4.9, 16.7, 
0.095 
10.1, 23.4 14.9, 27.6, 
0.845 
10.6, 21.5 -9.2, 26.6, 
0.399 
-4.8, 12.0 
Opening mouth 17.6, 27.5, 
0.248 
9.3, 15.3    40.2, 33.8, 
0.467 
39.1, 34.3 -19.5, 31.5, 
0.034 
-30.4, 37.5 
Dry mouth 29.4, 29.3, 
0.197 
41.3, 26.0 64.4, 33.3, 
0.042 
62.3, 27.2 -34.5, 32.7, 
0.528 
-23.2, 29.2 
Sticky saliva 27.3, 24.2, 
0.318 
34.7, 32.6 71.4, 31.1, 
0.168 
68.1, 34.1 -44.0, 31.5, 
0.387 
-37.7, 36.7 
Coughing 20.6, 16.4, 
0.087 
21.3, 27.0  35.6, 28.1, 
0.744 
43.5, 29.2 -12.6, 27.3, 
0.536 
-26.1, 26.5 
Felt ill 16.7, 22.1, 
0.707 
17.8, 22.2 43.7, 32.2, 
0.824 
45.5, 28.3 -29.9, 28.7, 
0.397 
-29.8, 27.1 
Pain killers     44.1, 50.4, 
0.752 
40.0, 50.0 86.7, 34.6, 
0.288 







36.0, 49.0 46.7, 50.7, 
0.123 
68.2, 47.7 -44.8, 50.6, 
0.543 
-36.4, 49.2 
Feeding tube 0.0,  0.0,  
0.037 
12.5, 33.8 30.0, 46.6, 
0.075 
54.5, 51.0 -27.6, 45.5, 
0.072 
-22.7, 68.5 
Weight gain 30.3, 46.7, 
0.311 
43.5, 50.7 7.4, 26.7, 
0.707 
4.8, 21.8 22.2, 57.7, 
0.394 
40.0, 50.3 
Weight loss 14.7, 35.9, 
0.181 
29.2, 46.4 62.1, 49.4, 
0.909 
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Table 5a General condition, skin and mucosal changes during radiation treatment for patients with BMI 
≥25 vs <25 
 0Gy 
 





Mean, SD, P-value 
 
ECOG performance 



























































 Mean, SD, P-value 
 Mucosal changes*,  
 BMI<25  



























































*none vs all grades combined                                                                                                                                                                                                                                          
Not provided standardized oral care information for prevention of mucositis  
 
   






Mean, SD, P-value 
 
 




1.6, 0.5, 0.269 






Mean, SD, P-value 
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no patients grade 3-4 at 0 Gy                                                                                                                                                                                                                                           
 
Table 6 Patients’ verbal answer about the instructions they received from health care providers before or 
during the treatment, converted to a three-tiered score. All patients received standardized oral care kits. 
Comparison between patients with BMI ≥25 vs <25 
Study specific 
questionnaire 
Start of treatment 
BMI≥25 
Mean, SD, P-value 
Start of treatment    
BMI<25  
Mean, SD 










1.7, 0.5, 0.104 
 
1.5. 0.5                                    
 





food and drinks that 


















   
    
    
    
Discussion 
During initial analyses of the prospective study [20-23], the authors developed a hypothesis that patients with normal 
and low BMI had more nutrition problems and therefore need more tube feeding than patients with overweight. The 
secondary analyses in the present exploratory study indicate that there were no significant differences, but they also 
show that BMI affected HRQOL and toxicity during radiation therapy. Head and neck cancer patients with high BMI 
(≥ 25) faced several challenges compared to patients with BMI < 25 before, during and after radiation treatment, 
except from mucosal changes after two weeks of treatment. This finding is in line with Fang et al. [26] who showed 
that higher BMI was associated with worse QOL for breast cancer patients before, during and after RT. The results 
are not consistent with those reported by Al-Naggar et al. [27] who examined QOL of breast cancer patients in 
Yemen and found a difference between underweight and overweight patients for emotional wellbeing. However, 
comparisons across both different disease types and cultures are difficult to interpret. 
Our study is the first to demonstrate that there is a connection between head and neck cancer patients’ BMI, their 
HRQOL and the individualized dietary counseling in the treatment period. The data presented here also illustrate that 
a considerable number of functions and symptoms are similar between the two BMI groups examined during RT for 
head and neck cancer. Before treatment overweight patients had more dyspnea than normal weight patients. As might 
be expected intuitively, lower rates of feeding tube use and lower intake of nutritional supplements were found in this 
subgroup. In a previous study, Van Bokhorst-de van der Schueren et al. [28] evaluated the use of perioperative 
nutritional support on QOL in 49 malnourished head and neck cancer patients. They found that patients who received 
preoperative tube-feeding and nutritional supplements experienced dyspnea relief [28]. Høgdal [29] has in a master 
thesis examined pretreatment HRQOL in 81 patients suffering from head and neck cancer. She found that these 
patients had more dyspnea before RT than normal population [29]. This finding might be related to the fact that half 
of these patients are smokers [29]. In Høgdals thesis [29] it was not focused on patients’ weight or BMI status. Other 
studies have also reported higher baseline dyspnea scores in head and neck cancer patients [25,30,31]. In our study 
patients with BMI  ≥ 25 had more dyspnea than patients with BMI < 25, in the absence of significant differences in 
smoking status between the groups (objective measures of lung function were not performed). This result can 
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possibly be explained by links between obesity and chronic diseases such as hypertension, coronary heart disease and 
congestive heart failure. Hammerlid et al [32] evaluated the connection between QOL and nutritional status and 
energy intake for head and neck cancer patients. They found no significant differences, but the malnourished patients 
scored worse on 12 of the 16 functional domains/symptoms [32].   
Besides dyspnea, we found significant differences between the two groups regarding use of nutritional supplements 
and feeding tubes at baseline. Tumor location and size might lead to nutritional difficulties before treatment [33,34]. 
Some studies have reported an association between poor nutrition and development of mucositis [35-37]. The 
potential mechanism of the association between BMI and oral mucositis is uncertain [38]. Oral mucositis is one of the 
most serious problems connected to head and neck cancer radiotherapy [39,40], and severe cases may require feeding 
tube placement. The data presented here, illustrate how oral mucositis develops in the two BMI groups during 
radiotherapy. At baseline there were no significant differences between the groups, but after two weeks of radiation 
treatment patients with BMI  ≥ 25 had less mucosal changes than patients with BMI < 25. After this time period, oral 
mucositis did not differ significantly between the groups. Saito et al. [38] examined whether low BMI could be a risk 
factor for oral mucositis. In their study, 33 patients with oral cancer received radiotherapy and they found that low 
BMI (< 22) may be a risk factor of moderate to severe oral mucositis. Virtually all patients who receive radiation 
therapy for head and neck cancer develop some degree of oral mucositis [39]. The incidence of oral mucositis has 
been reported to vary in relation to various patient characteristics, including low body mass index, altered oral intake 
and poor functional status, but the data supporting these potential non-dosimetric risk factors are inconsistent. At least 
in part, small group sizes and variations in RT technique and exposed mucosa surface might explain why variable 
correlations have been observed.    
In the present study a significant correlation was also shown between overweight and problems with opening mouth 
and less sexuality during radiation treatment. Høgdal [29] found comparable correlations in the same HRQOL 
domains. Since risk factors for restricted mouth opening in head and neck cancers include tumor location and 
proximity to relevant muscles [41] imbalances might confound QOL results, but we found no significant correlation 
between BMI and location or T stage.   
Our patients with BMI ≥ 25 had more problems with dry mouth after RT than patients with BMI < 25. This is 
interesting since there is a possibility that weight loss and contour changes in the neck region could account for 
accidental increase in dose to the salivary glands. This could explain the finding in the higher BMI group, but the 
number of patients was small. Kakoei et al. [42] highlighted the relationship between low QOL and dry mouth among 
patients irradiated for head and neck cancer. Head and neck cancer patients who underwent radiotherapy began to 
experience xerostomia after start of treatment, and this lead to a decrease in QOL during radiotherapy [42]. Previous 
studies have demonstrated that xerostomia, which is caused by permanent damage to the salivary glands in the 
irradiated region, is a common and important complaint amongst patients who undergo head and neck radiotherapy 
[43,44]. According to other studies, the effect of xerostomia on oral health and QOL is very important [42, 45]. In a 
study conducted in 2006, Pow et al. [44] compared the effect of intensity modulated radiotherapy (IMRT) vs. 
conventional radiotherapy on salivary flow and QOL. They found consistent improvement over time in the IMRT 
group, with xerostomia-related symptoms significantly less common than in the conventional radiotherapy group 
[44]. None of these studies have focused on patients’ BMI. We found no significant imbalance in IMRT use between 
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the two BMI groups. Possibly, in the absence of adaptive radiotherapy with re-planning based on new CT scans, 
obese patients might experience relatively larger changes in anatomy, which might result in higher than anticipated 
dose to the salivary glands [46].   
During treatment patients with BMI ≥ 25 received less information about food and drink that should be avoided than 
normal weight patients. The authors did not compare patient recollection with the actual nutritional advice and 
information provided, which is a weakness of our study. It is tempting to speculate that identical information policies 
would have contributed to better QOL and fewer side effects in overweight patients, which had less mucositis despite 
poorer counseling. However, this hypothesis needs prospective testing. Access to other sources of information 
including publicly available brochures and websites as well as communication with fellow patients might compensate 
for imbalances.    
The clinical manifestations of radiation injury and its nutritional consequences have been well described [47]. Several 
studies have shown a relationship between nutrition support, weight gain and improved QOL [48,49]. Ravasco et al. 
[7] performed a prospective randomized controlled trial with 75 patients with head and neck cancer to determine the 
effect of dietary counseling on outcome and QOL during and 3 months after radiotherapy [7]. They found that during 
RT, dietary counseling improved all QOL function scores in association with an adequate dietary intake and 
nutritional status [7]. The results from the present study provide important information about head and neck cancer 
patients treated with radiotherapy and the association of overweight with HRQOL, comparable to a previous breast 
cancer study [26]. Implications for practice include the need for health care providers to be aware of the impact that 
overweight and low weight has on patients’ HRQOL. Patients in the low BMI group had already commenced 
nutritional support with supplements and tube feeding before treatment, and this group continued to need greater 
nutritional support during treatment. Health care providers should be aware of patients’ need for nutritional 
information and support. A main limitation of our study is the short period of follow-up. Additional longitudinal 
studies should examine whether or not overweight patients persistently experience more problems with dry mouth 
and opening their mouth. Another weakness of the present study is the lack of information about patients’ compliance 
with dietary and oral care counseling. Regardless of BMI, all patients should be informed about nutritional 
recommendations during treatment and receive appropriate follow-up care and rehabilitation for reduced swallowing 
and mouth opening function. 
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